METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC)
Clinical trials for METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC) explained in plain language.
Never miss a new study
Get alerted when new METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC) trials appear
Sign up with your email to follow new studies for METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo targets tough prostate cancer in understudied groups
Disease control TerminatedThis study tested a combination of two drugs (niraparib and abiraterone plus prednisone) for men with metastatic hormone-sensitive prostate cancer that has certain gene mutations. It focused on Hispanic/Latino and Black patients, who are often underrepresented in research. The go…
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC)
Phase: PHASE2 • Sponsor: Qian Qin • Aim: Disease control
Last updated May 14, 2026 12:06 UTC
-
New scan study aims to personalize prostate cancer treatment
Knowledge-focused OngoingThis study tracks how well treatment is working in men with metastatic hormone-sensitive prostate cancer using special PET scans (PSMA-PET). Twenty participants will get a scan before starting standard therapy and another after 6 months. The goal is to see if these scans can help…
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC)
Phase: PHASE4 • Sponsor: Brigham and Women's Hospital • Aim: Knowledge-focused
Last updated May 15, 2026 11:58 UTC
-
Prostate cancer study tests if hormone pills boost scan brightness
Knowledge-focused OngoingThis study looks at whether giving hormone therapy to men whose prostate cancer has returned can make cancer cells more visible on a special PET scan. About 9 men will take a standard hormone pill for a few weeks and then get a scan to see if new spots light up. The goal is to le…
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC)
Phase: EARLY_PHASE1 • Sponsor: Beth Israel Deaconess Medical Center • Aim: Knowledge-focused
Last updated May 14, 2026 12:06 UTC
-
New study tracks heart risks of triple-drug therapy for advanced prostate cancer
Knowledge-focused OngoingThis study observes 100 Japanese men with metastatic hormone-sensitive prostate cancer who are already receiving darolutamide plus standard hormone therapy and chemotherapy. Researchers will track heart-related side effects and other medical problems during treatment. No extra vi…
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC)
Sponsor: Bayer • Aim: Knowledge-focused
Last updated May 12, 2026 13:41 UTC
-
Real-World study tracks Apalutamide's impact on prostate cancer patients
Knowledge-focused OngoingThis study follows 170 men with metastatic hormone-sensitive prostate cancer who choose to take apalutamide as part of their standard care. Researchers will measure how well the drug lowers PSA levels and how it affects fatigue, thinking skills, and overall quality of life using …
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC)
Sponsor: Royal Marsden NHS Foundation Trust • Aim: Knowledge-focused
Last updated May 04, 2026 16:23 UTC